XERS

Xeris Biopharma Holdings, Inc.

$8.69 -0.01 (-0.11%) At close · Jul 16

Market Cap

$1.50B

172,642,055

Up next

Next earnings call

Aug 6, 2026 Est · unconfirmed · in 3 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed May 7, 2026

AI Brief

TL;DR.

Bullish

Bearish

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 16.7 · calm Equity put/call 0.67

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +23%

above

Price vs 50-day avg +24%

above

RSI (14) 70

overbought

MACD trend Positive

52-week position 73%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Strong

1-month return +26%

trailing

6-month return +14%

trailing

YTD return +11%

this year

Relative strength +5%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $7 › 200d $7 — 200d above 50d

Institutional flow Accumulating

9 of 237 funds reported for Jun 30 · net +239.6K sh shares

Insider flow Distributing

Net -$607.0K over 90 days · 100% sells

Short interest Falling

7.39% of float · ▼ -0.4% MoM · 5.4 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

237 holders — near 3-yr high, broad support

Squeeze score 77

high risk · 0–100

Fundamentals

Strong

Revenue growth +143%

Y/Y

EPS growth +100%

Y/Y

Free cash flow $27.5M

Valuation P/E 124.1

rich

Balance sheet $109.3M

net debt

Quant / Vol

risk profile

Very High

Volatility 55%

annualized · 1-yr

Max drawdown −47%

past year

ATR 3.8%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record what management promised — and delivered

Latest guidance · from the 8-K filed May 7, 2026

Total revenue · full year 2026 Maintained $380M – $390M

prior FY $291.85M midpoint +31.9% Y/Y

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy

1 · 3 · 3

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+23% Bullish

Price vs 50-day avg

+24% Bullish

RSI (14)

70 Bearish

MACD trend

Positive Bullish

52-week position

73% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $7 › 200d $7 — 200d above 50d

Institutional flow Accumulating

9 of 237 funds reported for Jun 30 · net +239.6K sh shares

Insider flow Distributing

Net -$607.0K over 90 days · 100% sells

Short interest Falling

7.39% of float · ▼ -0.4% MoM · 5.4 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

237 holders — near 3-yr high, broad support

Price context

position in its 52-week range

52-wk low $5 Now $9 · 73% 52-wk high $10

vs 200-day avg +23% vs 50-day avg +24%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from its earnings releases, calls, and filings

Metric	Latest	Period	YoY
Adjusted EBITDA non-GAAP	$15.1M	Q1 2026	—

Gross margin	87%	Q1 2026	—
Total Shares Outstanding	172,642,055	April 30, 2026	—
patients on therapy (Recorlev®)	700	Full Year 2025	—

Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
XERS Xeris Biopharma Holdings, Inc. this stock	$1.50B	+10.7%	+142.7%	124.1	7.4%
TAK Takeda Pharmaceutical Co Ltd	$53.43B	+7.3%	—	—	0.2%
JHPCY Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR	$51.90B	—	—	—	0.0%
GALDY Galderma Group AG/ADR	$49.13B	+1.1%	—	—	0.0%
HLN Haleon plc	$44.52B	+0.0%	—	—	0.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

237

% held: 61.9%
Reported: 9 of 237
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

164

View

Short & Settlement

Short Interest Falling

Shares short

12.8M

Days to cover: 5.4d
Change: -50.0K sh

View

Short Volume

Short vol %

51%

As of: Jul 16, 2026

Short Total

View

Fails to Deliver

FTD shares

5.1K

Value: $39.2K
As of: Jun 29, 2026

View

Off-Exchange

Off-exchange %

40.2%

Week of: May 4, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$607.0K

Buyers / Sellers: 0 / 5

Buyers Sellers

View

Financials

Revenue (FY)

$291.8M

Net income (FY): $554.0K
EPS diluted: $0.00

View

Filings

SEC Filings

Latest

8-K

Filed: Jun 30, 2026
This year: 11

View

Proposed Sales

Value

$231.0K

Shares: 27.6K
Filed: Jul 7, 2026

View

Earnings & Events

Earnings Calls

Last call

May 7, 2026

View

Performance

	5D	20D	120D	MTD	YTD
XERS	+0.8%	+25.9%	+14.2%	+9.7%	+10.7%
SPY	-0.1%	+0.1%	+9.0%	+0.5%	+10.1%
vs SPY	+0.9%	+25.9%	+5.2%	+9.2%	+0.6%

Key facts CIK 1867096 CUSIP 98422E103 13F (30d) 10 filings 10 filers Visit website Investor relations

XERS

Price & Indicators

Technicals

Key metrics

Versus peers

At a glance

Performance